ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Pharmion Submits European Marketing Authorization Application (MAA) For Vidaza(R) In Patients With Higher Risk Myelodysplastic Syndromes (MDS)
Pharmion Corporation
(Nasdaq: PHRM) announced the submission of a MAA with the European
Medicines Agency (EMEA) for Vidaza(R) (azacitidine for injection) in the
treatment of patients with higher-risk MDS in the European Union (EU).
"We are pleased to submit this application to the EMEA, given the
highly compelling data for Vidaza in the treatment of MDS," said Patrick J.
Mahaffy, Pharmion's president and chief executive officer. "Vidaza is the
only hypomethylating agent, and, in fact, the only drug to have shown an
improvement in overall survival in this indication, and we believe it will
become the standard of care throughout Europe for higher-risk MDS."
"Our study results presented late last year at the American Society of
Hematology meeting confirm that Vidaza should be considered first-line
therapy for patients with higher-risk MDS," said Pierre Fenaux, M.D.,
Professor of Hematology at the University of Paris, and Head, Department of
Clinical Hematology, Hopital Avicenne, France, and principal investigator
of the Phase 3 study. "Overall survival is the gold standard by which
clinical benefit should be measured for patients, and these data
demonstrate the tremendous benefit that Vidaza can provide these patients;
this represents a significant advance in the treatment of MDS patients."
Vidaza has been designated as an Orphan Medicinal Product in the EU for
the treatment of MDS, which, if approved, entitles the drug to ten years of
market exclusivity for the approved indication. Vidaza has also been
designated as an Orphan Medicinal Product in the EU for the treatment of
acute myeloid leukemia (AML).
The application is based upon clinical data which includes the results
from the Company's Phase 3 multi-center, international, randomized study of
Vidaza(R) (azacitidine for injection) in the treatment of patients with
higher-risk MDS. The primary objective of this Phase 3 trial was to
demonstrate superiority in overall survival of Vidaza versus CCR. The study
included 358 patients at sites in the U.S., Europe, and Australia. At
baseline, approximately 90 percent of patients were considered to have
higher- risk MDS, based on subsequent independent review of FAB subtypes or
IPSS classification. Patients were assigned to treatment with Vidaza
(N=179; 75 mg/m2/day SC for seven consecutive days every 28 days) or CCR.
Patients assigned to CCR could receive either BSC alone (N=105), low-dose
cytarabine (LDAC; N=49), or standard chemotherapy (Std Chemo; N=25). The
median number of cycles for Vidaza was nine; the median number of cycles
for the CCR arm was as follows: BSC seven cycles, LDAC 4.5 cycles and Std
Chemo one cycle.
With a median follow-up of 21.1 months, Vidaza demonstrated a
statistically significant overall survival advantage over CCR (24.4 months
vs. 15 months; stratified log rank p=0.0001).The hazard ratio describing
this treatment effect was 0.58 (95 percent confidence interval of 0.43 to
0.77). At two years, Vidaza demonstrated a two-fold advantage in overall
survival over CCR (51 percent vs. 26 percent; log rank p
Pharmion Prezintã Europene autorizaþie de introducere pe piaþã Application (MAA) Pentru Vidaza (R), la pacienþii cu risc mai mare Myelodysplastic sindroame (MDS) - Pharmion Submits European Marketing Authorization Application (MAA) For Vidaza(R) In Patients With Higher Risk Myelodysplastic Syndromes (MDS) - articole medicale engleza - startsanatate